medicines an investment in health The Stakeholder Handbook Your Pharmaceutical Industry Reference Source
medicines an investment in health The Stakeholder Handbook Your Pharmaceutical Industry Reference Source
IPHA Stakeholder Handbook First Edition
The Irish Pharmaceutical Healthcare Association (IPHA), the representative body for the research-based pharmaceutical industry in Ireland, has compiled the Stakeholder Handbook with a view to providing assistance to interested parties with enquiries relating to the industry. In the following sections you will find listings of key contacts within IPHA, IPHA member companies, Government, health and enterprise agencies, regulatory bodies, professional healthcare and enterprise organisations, voluntary healthcare organisations, patient organisations, international pharmaceutical associations and other global healthcare groups. In addition to key contacts within each of the above listed organisations the Stakeholder Handbook also provides key facts and figures relating to the Irish pharmaceutical and healthcare sectors.
2
The purpose of the Stakeholder Handbook is to provide a comprehensive guide to company and industry resources in order to help answer any queries you may have relating to the prescription medicines and/or consumer healthcare industries. We hope that you find this source of use in the coming year and we welcome your calls on any industry issue.
Ronan Collins COMMUNICATIONS MANAGER
Whilst every effort is made to ensure the accuracy of the entries in this publication IPHA is not to be held liable in damages or otherwise for omissions or incorrect insertion, whether as to wording, space or position of any entry.
3
Contents Introduction
SECTION ONE: MEDICINES Medicines in the Health System The Medicines Industry About IPHA International Associations
7 13 19 23
SECTION TWO: IPHA MEMBER COMPANIES Member Companies details including Media Contacts Member Company by Therapeutic Category
27 37
SECTION THREE: HEALTH CONTACTS Healthcare in Ireland Today Government and Opposition Spokespersons for Health & Children Joint Oireachtas Committee on Health and Children Department of Health and Children About the Department of Health and Children Government Health and Children Ministers Department of Health and Children Divisions The Role of Agencies in the Department of Health and Children Department of Health and Children Statutory Agencies Department of Health and Children Non-Statutory Agencies Hospital Boards
54 55 56 81 81 84 84 84
The Health Information and Quality Authority (HIQA)
85
Health Service Executive (HSE) About the HSE HSE Organisational Structure HSE Board HSE Divisions
87 88 89 89
Regulatory Authorities Professional Healthcare Organisations Voluntary Health and Patient Organisations
4
47 48 51
102 102 105
SECTION FOUR: ENTERPRISE CONTACTS 117 Medicines Industry in Ireland Today Government and Opposition Spokespersons for Enterprise, Trade 118 and Employment Joint Oireachtas Committee on Enterprise Trade and Employment 120 Department of Enterprise Trade and Employment About the Department of Enterprise Trade and Employment Government Enterprise Trade and Employment Ministers Department of Enterprise Trade and Employment Divisions Department of Enterprise Trade and Employment Agencies
123 124 125 149
European Union Members of the European Parliament European Union Institutions European Union Agencies
151 153 154
Innovation and Translational Medicines Colleges of Research Centres for Science Engineering and Technology Clinical Research Centres Ethics Committees Facilitators/Collaborations Investors Funding Agencies
154 161 162 163 166 167 169
SECTION FIVE: MEDIA CONTACTS Specialised Medical and Health Print Media National and Sunday Print Media Television Media Contacts Radio Media Contacts
171 172 177 178
5
The Stakeholder Handbook
6
Section 1 Medicines
section one Medicines
Medicines in the Health System “It is our duty to ensure that, in healthcare, new innovative medicines benefit as many patients as possible, as quickly as possible – so that our true productivity, in terms of patient lives transformed, continues to rise.” Dr Gerald Farrell, IPHA President 7
The Stakeholder Handbook
INNOVATIVE MEDICINES AND VACCINES Innovative medicines and vaccines are an integral and increasingly important part of the Irish healthcare system. They prevent, treat and cure disease, improve quality-of-life, control pain and suffering and save lives. And, in the context of limited healthcare resources, access to medicines can empower patients to manage more of their own care with timely, effective and convenient treatment. The timely use of innovative medicines and vaccines has: •
Helped to improve life expectancy in Ireland by over a third in the last eighty years, from 57 in 1925 to 79 today1.
•
Enabled Irish hospitals to treat patients on a day case basis, from 85,000 cases in 1987 to an estimated 590,000 in 20072.
•
Helped thousands of Irish patients with Parkinson's, Alzheimer's, ulcers, cancer, diabetes and mental illness to lead better and more normal lives, eliminated in some cases the need for costly, painful surgery, eased the burden on care-givers, delayed or avoided costly long-term nursing care and saved the State millions in healthcare costs.
•
Contributed to reducing the number of deaths from heart disease and stroke by nearly a half3 (the number one cause of death in Ireland).
•
Reduced the rate of death for heart attack patients in hospitals by nearly 45% and the rate of subsequent heart attacks in a period of six months following initial treatment by 60% in just six years.4
•
Helped to protect millions of people from disease, yet the search continues for vaccines that will halt the spread of cancer and diseases such as malaria and AIDS.
•
Ensured that previously leading causes of death such as pneumonia, TB, polio and measles can now be successfully treated globally.
1
8
2 3 4
CSO Statistics HSE Annual Report 2007 www.hse.ie/en/FactFileHome/HSEApproach/HSEModelofCare (accessed 24 October 2007) Journal of the American Medical Association
Section One – Medicines
The alternative to the use of innovative medicines is not cost free; it may involve longer hospital stays, longer less effective treatments, invalidity, sick pay and a poorer quality of life.
The medicines bill in Ireland is low by international standards Total State expenditure on medicines (2007)5
€1,703 million
Expenditure on medicines as a % of state health expenditure
10.9%
European average6
15.9%
There are straightforward reasons for the increase in the State bill for medicines in recent years: •
Ireland’s rapidly increasing and ageing population.
•
The availability of newer, better medicines.
•
Ireland’s low base of poor life expectancy and low levels of utilisation of medicines.
•
The increasing incidence of chronic and non-communicable diseases such as asthma, diabetes and obesity.
•
State decisions to enhance eligibility and alter the administration of certain community drug schemes, for example the decision to grant medical cards to everyone over 70 years old.
•
The increasing research and development costs of new innovative medicines, up from €344 million in 1987 to €1,059 million in 20067.
5 6 7
Primary Care Reimbursement Service Annual Report 2007 EFPIA – The Pharmaceutical Industry in Figures 2007 Edition J.A. DiMasi and H.G. Grabowski, ‘The Cost of Biopharmaceutical R&D: Is Biotech Different?, Price of Innovation: New Estimates of Drug Development Costs’, Managerial and Decision Economics 28 (2007): 469-479.
9
The Stakeholder Handbook
MEDICINES IN SELF-CARE Consumers want to actively manage their own health and are taking greater individual responsibility for their healthcare and health choices. The health, social and economic benefits of responsible self-medication are well known and have been extensively reported8. -
Patients and consumers benefit due to wellness, enhanced productivity and improved health in terms of prevention and increased patient satisfaction as a result of being able to obtain the correct medication directly.
-
Employers gain by having employees attend work when they might otherwise have stayed at home.
-
General Practitioners save time which enables them to better use that time for those patients with complicated or serious illnesses. A recent report estimated that 51.4 million GP consultations in the UK were solely for minor ailments. It estimated that this represented 18% of a GP’s workload. Furthermore it estimated that the total cost to the NHS of these consultations was €2.5 billion and 80% of this cost (€2.15 billion) related to the cost of the GP’s time.9 It also presents more of an opportunity for doctors to educate patients about common ailments and diminishes patient expectations of a prescription for every visit.
-
Pharmacists play a more active advisory role using their skilled knowledge of medicines and expertise in advising on symptoms.
-
Consumers pay less visits to accident and emergency departments and doctor surgeries. This in turn reduces the number of prescriptions, most of which are paid for, directly or indirectly, by the State.
The basis of responsible self-medication is that the consumer has the appropriate information to select and use non-prescription medicines correctly. To ensure that they realise that a safe and effective remedy may be available for their minor ailment and do
8
10
9
E.g. Guiding Principles in Self-Medication: WSMI: http://www.wsmi.org/publications.htm Minor ailments cost the NHS £2 billion/year. Pharm J 2008; 280:1090
Section One – Medicines
not suffer in silence unnecessarily, appropriate information about non-prescription medicines is provided to consumers through pack information, advertising, public education initiatives and through their pharmacist. These different information sources complement each other and provide the appropriate safeguards to ensure the safe use of self-medication products.
11
The Stakeholder Handbook
12
The Medicines Industry “Here in Ireland, we have placed R&D at the heart of our economic development strategy in recent years.‌The bottom line is that we in Ireland strive to become leaders in the global knowledge economy. In order to do this, we will continue to invest in the people and supports that have earned us our reputation to date as a good place to do business.â€? Mr Bertie Ahern, Former Taoiseach
13
The Stakeholder Handbook
PHARMA IRELAND Ireland’s medicines industry currently generates nearly 50 percent of the country's exports which contributes to making Ireland the largest net exporter of medicines in the world.
Direct Employment10 Employment in the sector has grown from 5,200 in 1988 to 24,500 in 2007. Upwards of a further 24,500 jobs are based on the provision of services to the sector. Employment growth has exceeded 1,000 for each of the last nine years. Over half of the employees are third level graduates.
24,500
Pharmaceutical Exports11 Nearly €1 in every €6 worth of Irish exports in 2006 €14.8 billion consisted of pharmaceutical and medical products. Using the broader pharmachem measure exports came to nearly €42.7 billion. Ireland is the largest net exporter of pharmaceuticals in the world12.
10
14
11 12
Pharmachemical Ireland CSO Statistics World Trade Organisation
Section One – Medicines
World Trade in Pharmaceuticals 2005 Country Ireland Switzerland Germany UK France Sweden Austria Netherlands Italy Belgium Spain Japan USA
Exports $ 17,994 25,131 37,506 22,487 22,912 7,192 4,507 11,074 13,135 35,024 5,933 3,327 25,946
Imports $ 2,484 12,983 30,097 15,964 17,040 2,720 4,207 11,301 13,870 35,804 8,844 8,204 39,323
Balance $ 15,510 12,148 7,409 6,523 5,872 4,472 300 -227 -735 -780 -2,911 -4,877 -13,377
Annual Taxation Payments13 These tax payments amount to nearly twice the overall State bill for medicines.
€3 billion
Replacement value of the investment by the pharmaceutical sector in the Irish Economy14 13 of the top 15 companies in the world have substantial operations in Ireland.
€40 billion
Nearly €7 billion has been invested by the sector in Ireland over the last nine years.
13 14
IPHA estimate based on an analysis of CSO and IDA Ireland data Ibid 11
15
“If Ireland is serious about meeting its objective of increasing its level of innovation, focus needs to continue to be placed on creating an environment where investment is welcome, R&D is fostered, and innovative ideas are valued and protected.� Dr Gerald Farrell, IPHA President
16
Section One – Medicines
PHARMA RESEARCH AND DEVELOPMENT Research based pharmaceutical companies are the engines of medicines innovation. They have discovered and developed over 90% of all new medicines made available to patients worldwide over the last twenty years. The discovery, development, testing and gaining of regulatory approval for new medicines has become an even more highly complex, lengthy, risky and expensive process. Each success is built on many, many prior failures. On average only one or two of every 10,000 promising substances will successfully pass extensive testing in the R&D phase to be approved as a marketable product. As such the cost of developing a medicine has gone from €149 million in 1975 to €1,059 million in 200615.
COST OF DEVELOPING A NEW MEDICINE 1200 1,059 1000 868 Millions
800 600 344
400 149
200 0
1975
2001
1987
2006
Year
It takes an average 10 to 12 years to develop a new medicine from the time it is discovered to when it passes the regulatory standards of safety, quality and efficacy and is available to patients. Once on the market the average medicine has only 8 to 10 years of effective patent protection left before facing generic competition. Only three out of ten marketed medicines produce revenues that match or exceed their R&D costs before they lose patent protection.
15
J.A. DiMasi and H.G. Grabowski, ‘The Cost of Biopharmaceutical R&D: Is Biotech Different?, Price of Innovation: New Estimates of Drug Development Costs’, Managerial and Decision Economics 28 (2007): 469-479.
17
The Stakeholder Handbook
From concept to product: steps in the genesis of a medicine
10,000 molecules screened
100 molecules tested
10 candidate molecules 1 medicine
Research phase 0
Test phase 5 years 10 years R&D
Patent filing
Development phase 10 years
Administrative Procedures
Commercialisation phase 20 years
15 years 2 to 3 years
Patent expiry
Innovation is central to the creation of the knowledge based economy of the 21st century. For example in Ireland pharmaceutical industry R&D is responsible for 20% of all business R&D. If innovation is to flourish then it must be rewarded. Whilst Ireland retains a proinnovation outlook this is increasingly not the case in Europe generally with patient access to new medicines via State reimbursement systems being delayed or even denied entirely. As a result of this less favourable climate for innovation more and more pharmaceutical companies, including European ones, are deciding to locate new R&D facilities outside Europe.
18
About IPHA “The wide availability and accessibility of innovative medicines allows greater choice and therapeutic precision in healthcare and continues to play an increasingly value-added role in healthcare delivery.� Ms Anne Nolan, IPHA Chief Executive 19
The Stakeholder Handbook
The mission of the Irish Pharmaceutical Healthcare Association (IPHA) is to create a favourable economic, regulatory and political environment which will enable the international research-based pharmaceutical industry in Ireland to meet the growing healthcare needs and expectations of patients. IPHA aims also to develop an appreciation of the value of medicines, in particular innovative medicines, to healthcare and society as a whole thereby ensuring patients' continued, timely access to the full range of available medicines, regardless of their ability to pay.
IPHA represents the interests of the international researchbased pharmaceutical industry: IPHA’s main activity is to ensure that the views and interests of the research based pharmaceutical industry are recognised by those institutions, at home and abroad, who are involved in pharmaceutical and healthcare matters.
Builds relationships with other partners in healthcare: IPHA maintains regular contacts with all relevant institutions in and outside Ireland.
Participates in the healthcare decision making process: IPHA is regularly consulted in draft decisions made for example by the Department of Health & Children and other Government agencies which relate to pharmaceutical and health matters.
Ensures the highest possible standards of advertising and promotion: IPHA administers a number of Codes of Practice including the Code of Marketing Practice for the Pharmaceutical Industry and the Code of Advertising Standards for the Consumer Healthcare Industry. The objective of these Codes is to ensure the highest possible standard in advertising and promotion of medicines.
Keeps the healthcare professions up-to-date: IPHA publishes the IPHA Medicines Compendium on CD-ROM every year for distribution free of charge, to members of the medical and pharmacy professions. As well as this IPHA maintain an online version of the Compendium (www.medicines.ie). IPHA members are committed to supporting the continuing medical education of healthcare professionals.
20
Section One – Medicines
Ensures supply of the full range of modern medicines: The members of IPHA have entered into a binding agreement with the HSE to provide the best possible value for money in relation to the purchasing of medicines for the health services in Ireland.
For more information, contact: Irish Pharmaceutical Healthcare Association Franklin House 140 Pembroke Road Ballsbridge Dublin 4 Tel (+353) (0)1 660 3350 Fax (+353) (0)1 668 6672 Email: info@ipha.ie Anne Nolan Chief Executive Tel: (+353) (0)1 660 3350 Email: annenolan@ipha.ie Brian Murphy Director of Commercial Affairs Tel: (+353) (0)1 663 0939 Email: brianmurphy@ipha.ie Dr Rebecca Cramp Scientific and Regulatory Affairs Manager Tel: (+353) (0)1 663 0932 Email: rebeccacramp@ipha.ie Ronan Collins Communications Manager Tel: (+353) (0)1 663 0936 Email: ronancollins@ipha.ie Michelle Kurtz Communications and Marketing Executive Tel: (+353) (0)1 663 0934 Email: michellekurtz@ipha.ie
21
The Stakeholder Handbook
Sabine Louet Head of Code Services and Innovation Tel: (+353) (0)1 663 0933 Email: sabinelouet@ipha.ie Visit our various websites:
www.ipha.ie
www.medicinesandyou.ie
22
www.medicines.ie
www.feelbetter.ie
Section One – Medicines
INTERNATIONAL ASSOCIATIONS
Association of European Self-Medication Industry (AESGP) 7 Avenue de Tervuren B-1040 Brussels Belgium Tel: (+32) (2) 735 51 30 Fax: (+32) (2) 735 52 22 Email: info@aesgp.be Website: www.aesgp.be The Association of European Self-Medication Industry (AESGP) was established in 1964 to contribute to the improvement of responsible self-medication at a European level. AESGP comprises national organizations (full members) and several associate members representing the main international companies operating in the area of self-care, self-medication and food supplements. AESGP represents the interests of its members in a way that facilitates consumers’ access to high quality, safe and effective consumer healthcare products. Media Contact Ms Mary Coronel Communications and Public Relations AESGP 7 Avenue de Tervuren B-1040 Brussels Belgium Tel: (+32) (0)2 735 51 30 Fax: (+32) (0)2 735 52 22 Email: m.coronel@aesgp.be
23
The Stakeholder Handbook
European Federation of Pharmaceutical Industries and Associations (EFPIA) Leopold Plaza Building Rue du Tr么ne 108 B-1050 Brussels Belgium Tel: (+32) (0)2 626 25 55 Fax: (+32) (0)2 626 25 66 Email: info@efpia.org Website: www.efpia.eu The European Federation of Pharmaceutical Industries and Associations (EFPIA) has a direct membership of 32 national pharmaceutical industry associations and 43 leading pharmaceutical companies. EFPIA represents about 2,200 companies in Europe committed to researching and developing new medicines that improve health and quality of life around the world. The mission of EFPIA is to improve the competitiveness of the research-based pharmaceutical industry in Europe in a regulatory and political environment, which above all stimulates R&D and rewards innovation. Media Contact Colin MacKay Director of Communication and Partnerships EFPIA Leopold Plaza Building Rue du Tr么ne 108 B-1050 Brussels Belgium Tel: (+32) (0)2 626 25 55 Fax: (+32) (0)2 626 25 66 Email: colinmackay@efpia.org
24
International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) 15 Ch. Louis-Dunant PO Box 195 1211 Geneva 20 Switzerland Tel: (+41) 22 338 32 00 Fax: (+41) 22 338 32 99 Email: admin@ifpma.org Website: www.ifpma.org The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) is an organisation representing 60 national or regional pharmaceutical industry associations and companies from both developed and developing countries. Member companies of the IFPMA are research-based pharmaceutical, biotech and vaccine companies. IFPMA strives to create a global environment that fosters innovation, drug regulation, market-based competition in the health care sector, the dissemination of drug information, ethical promotion of drugs, patient access to innovative therapies and protection from substandard and counterfeit products. Media Contact Guy Willis Director of Communications IFPMA 15 Ch Louis Dunant PO Box 195 1211 Geneva 20 Switzerland Tel: (+41) 22 338 32 00 Fax: (+41) 22 338 32 99 Email: g.willis@ifpma.org
25
The Stakeholder Handbook
26
Section 2 IPHA Member Companies
section two IPHA Member Companies
Section Two – IPHA Member Companies
MEMBER COMPANIES DETAILS INCLUDING MEDIA CONTACTS IPHA comprises of 53 research-based pharmaceutical companies which includes both manufacturers of prescription medicines and non-prescription or consumer healthcare medicines. This section contains all IPHA member companies and provides the point(s) of contact for media queries within each individual company. A Menarini Pharmaceuticals Ireland Ltd Castlecourt Monkstown Farm Monkstown Co Dublin Tel: (+353) (0)1 284 6744 Fax: (+353) (0)1 284 6769 Media Contact Contact Main Number Abbott Laboratories (I) Ltd 4051 Kingswood Drive Citywest Business Campus Dublin 24 Tel: (+353) (0)1 469 1500 Fax: (+353) (0)1 469 1501 Primary Media Contact Name: Carmel Mulroy Tel: (+353) (0)1 469 1500 Mob : (+353) (0)86 605 8040 Fax: (+353) (0)1 469 1538 Email: Carmel.mulroy@abbott.com Secondary Name: Paula Guerin Tel: (+353) (0)1 469 1586 Fax: (+353) (0)1 469 1538 Email: Paula.guerin@abbott.com
Allergan Pharmaceuticals Ireland Ltd Castlebar Road Westport Co. Mayo Tel: (+353) (0)98 25 222 Fax: (+353) (0)98 25 792 Website: www.allergan.com Primary Media Contact Name: Pat O’Donnell Tel: (+353) (0)98 55 201 Mob: (+353) (0)87 243 2594 Fax: (+353) (0)98 26 744 Email: odonnell_pat@allergan.com Secondary Name: Shauna Crossan Tel: (+353) (0)98 55 419 Mob: (+353) (0)87 616 5961 Fax: (+353) (0)98 26 744 Email: Crossan_shauna@allergan.com Alliance Pharmaceuticals Ireland Avonbridge House Bath Road Chippenham Wiltshire SN15 2BB UK Tel: (+44) 1 249 466 966 Fax: (+44) 1 249 466 977 Website www.alliancepharma.co.uk Media Contact Contact Main Number
27
The Stakeholder Handbook
Amgen Ireland Limited 21 Northwood Court Santry Dublin 9 Tel: (+353) (0)1 852 7400 Fax: (+353) (0)1 852 7499 Media Contact Name: Anette Condon Mob: (+353) (0)87 284 1951 Email: acondon@amgen.com Astellas Pharma Ltd 25 The Courtyard Kilcarbery Business Park Clondalkin Dublin 22 Tel: (+353) (0)1 467 1555 Fax: (+353) (0)1 467 1550 Media Contact Name: Patricia Kelly Tel: (+353) (0)1 467 1555 Fax: (+353) (0)1 467 1550 AstraZeneca Pharmaceuticals (Ireland) Ltd College Park House 20 Nassau Street Dublin 2 Tel: (+353) (0)1 609 7100 Fax: (+353) (0)1 679 6650 Website: www.astrazeneca.com Media Contact Contact Main Number Bayer Consumer Care The Atrium Blackthorn Rd Sandyford Estate Dublin 18 Tel: (+353) (0)1 206 1445
28
Media Contact Name: Niamh Griffin Tel: (+353) (0)1 299 9313 Fax: (+353) (0)1 206 1456 Email: niamh.griffin@bayerhealthcare.com Bayer Schering Pharma The Atrium Blackthorn Rd Sandyford Estate Dublin 18 Media Contact Name: Niamh Griffin Tel: (+353) (0)1 299 9313 Fax: (+353) (0)1 206 1456 Email: niamh.griffin@bayerhealthcare.c om Biogen Idec (Ireland) Ltd United Drug House Magna Drive Magna Park Citywest Road Dublin 24 Tel: (+353) (0)1 463 7799 Fax: (+353) (0)1 481 1730 Primary Media Contact Name: Paula Cobb Tel: (+353) (0)1 463 7725 Mob: (+353) (0)86 384 1973 Fax: (+353) (0)1 481 1730 Email: Paula.cobb@biogenidec.com Secondary Name: Siani Blanchfield Tel: (+353) (0)59 91 33017 Mob: (+353) (0)87 243 4900 Fax: (+353) (0)59 91 33519 Email: Siani.Blanchfield@biogenidec.com
Section Two – IPHA Member Companies
Boehringer Ingelheim Ireland Limited Corrig Court Corrig Road Sandyford Industrial Estate Dublin 18 Tel: (+353) (0)1 295 9620 Fax: (+353) (0)1 295 9624 Media Contact Contact Main Number Bristol-Myers Squibb Pharmaceuticals South County Business Park Leopardstown Dublin 18 Tel: (+353) (0)1 291 3800 Fax: (+353) (0)1 291 3899 Media Contact Name: Fred Doherty Tel: (+353) (0)1 291 3800 Fax: (+353) (0)1 291 3899 Email: Fredick.doherty@bms.com Celgene Limted Morgan House Madeira Walk Sheet Street Windsor Berkshire SL4 1BE UK Tel: (+44) 1 753 498 600 Fax: (+44) 1 753 861 484 Media Contact Name: Andrew Robertson Tel: (+44) 1 753 498 600 Mob: (+44) 7 917 436 395 Fax: (+44) 1 753 861 484 Email: arobertson@celgene.com
Cephalon Pharma (Ireland) Limited Unit E Glencormack Business Park Kilmacanogue Co Wicklow Tel: (+353) (0)1 201 4000 Fax: (+353) (0)1 201 4040 Media Contact Name: Marie-Dominique de La Salle Tel: (+33) 86 71 8248 Fax: (+33) 86 71 8090 Email: mddelasalle@cephalon.com Eisai Limited 3 Shortlands Hammersmith International Centre London W6 8EE England Tel: (+44) 2 08 600 1400 Fax: (+44) 2 08 600 1401 Media Contact Name: Andrew Day Tel: (+44) 2 08 600 7395 Mob: (+44) 7 973 411 419 Fax: (+44) 2 08 600 7300 Email: andrew_day@eisai.net Eli Lilly & Company (Ireland) Ltd Hyde House 65 Adelaide Road Dublin 2 Tel: (+353) (0)1 661 4377 Fax: (+353) (0)1 661 4476 Media Contact Contact Main Number
29
The Stakeholder Handbook
GlaxoSmithKline Stonemason’s Way Rathfarnham Dublin 16 Tel: (+353) (0)1 495 5000 Fax: (+353) (0)1 495 5105 Media Contact Name: Claire Taaffe Tel: (+353) (0)1 495 5218 Mob: (+353) (0)86 805 3251 Email: Claire.l.taaffe@gsk.com GlaxoSmithKline Consumer Healthcare Stonemason’s Way Rathfarnham Dublin 16 Tel: (+353) (0)1 495 5000 Fax: (+353) (0)1 495 5105 Media Contact Name: Niall O’ Shea Tel: (+353) (0)1 495 5208 Mob: (+353) (0)86 170 1784 Fax: (+353) (0)1 495 5575 Email:niall.p.oshea@gsk.com Grünenthal Pharma Ltd Pharmapark Chapelizod Dublin 20 Tel: (+353) (0)1 630 5392 Fax: (+353) (0)1 630 5317 Media Contact Name: Tom Coogan Tel: (+353) (0)1 630 5392 Mob: (+353) (0)87 912 8560 Fax: (+353) (0)1 630 5415 Email: Tom.coogan@grunenthal.com
30
Helsinn Birex Therapeutics Ltd Unit 5B Damastown Mulhuddart Dublin 15 Tel: (+353) (0)1 822 5417 Fax: (+353) (0)1 822 5413 (+353) (0)1 822 5410 Media Contact Contact Main Number Ipsen Pharmaceuticals Limited 7 Upper Leeson Street Dublin 4 Tel: (+353) (0)1 668 1377 Fax: (+353) (0)1 660 2818 Primary Media Contact Name: Alan Bass Tel: (+353) (0)1 668 1377 Mob: (+353) (0)86 246 0420 Fax: (+353) (0)1 660 2818 Email: alan.bass@ipsen.ie Secondary Name: Susan Aughney Tel: (+353) (0)1 668 1377 Mob: (+353) (0)86 260 2934 Fax: (+353) (0)1 660 2818 Email: susan.aughney@ipsen.ie Janssen-Cilag Limited Block B Liffey Valley Office Park Quarryvale Co. Dublin Tel: (+353) (0)1 623 1315 Fax: (+353) (0)1 626 3592 Media Contact Name: Dr Leonie Rynn Tel (+353) (0)1 620 2308 Mob: (+353) (0)87 833 9174 Fax: (+353) (0)1 626 3592 Email: lrynn@jacgp.jnj.com
Section Two – IPHA Member Companies
Secondary Name: Dr Leisha Daly Tel: (+353) (0)1 620 2302 Mob: (+353) (0)87 677 7928 Fax: (+353) (0)1 626 3592 Email: ldaly@jacgb.jnj.com Labopharm Europe Limited 5 Seapoint Building 44 Clontarf Road Dublin 3 Tel: (+353) (0)1 854 0158 Fax: (+353) (0)1 854 0144 Website: www.labopharm.com Media Contact Contact Main Number LEO Pharma 285 Cashel Road Dublin 12 Tel: (+353) (0)1 490 8924 Fax: (+353) (0)1 490 1606 Media Contact Contact Main Number Lundbeck (Ireland) Ltd 7 Riverwalk Citywest Business Campus Citywest Dubiln 24 Tel: (+353) (0)1 468 9800 Fax: (+353) (0)1 468 9850 Primary Media Contact Name: Darina Kelly Tel: (+353) (0)1 468 9800 Mob: (+353) (0)86 852 0079 Fax: (+353) (0)1 468 9850 Email: dake@lundbeck.com Secondary Name: Deirdre Moran Tel: (+353) (0)1 468 9800 Mob: (+353) (0)86 381 1805 Fax: (+353) (0)1 468 9850 Email: dmor@lundbeck.com
MEDA Office 10 Dunboyne Business Park Dunboyne Co Meath Tel:(+353) (0)1 802 6624 Fax: (+353) (0)1 802 6629 Media Contact Contact Main Number Merck Serono 3013 Lake Drive Citywest Business Campus Naas Road Dublin 24 Tel: (+353) (0)1 466 1910 Fax: (+353) (0)1 466 1902 Media Contact Contact Main Number Merck Sharp & Dohme Ireland (Human Health) Ltd Pelham House South County Business Park Leopardstown Dublin 18 Tel: (+353) (0)1 299 8700 Fax: (+353) (0)1 299 8701 Media Contact Name: Ciara O’ Rourke Tel: (+353) (0)1 299 8706 Mob: (+353) (0)86 388 7004 Fax: (+353) (0)1 299 8701 Email: Ciara_orourke@merck.com
31
The Stakeholder Handbook
Mundipharma Pharmaceuticals Company Millbank House Arkle Road Sandyford Dublin 18 Tel: (+353) (0)1 206 3800 Fax: (+353) (0)1 294 5104 Primary Media Contact Name: Ian A. Sutton Tel: (+353) (0)1 206 3800 Fax: (+353) (0)1 294 5104 Email: ian.sutton@mundipharma.ie Secondary Name: Rob Cohen Tel: (+44) 1 223 424 211 Email: rob.cohen@mundipharma.co.uk Novartis Consumer Health Regus House Harcourt Road Dublin 2 Tel: (+353) (0)1 477 3054 Fax: (+353) (0)1 402 9448 Media Contact Contact Main Number Novartis Ireland Ltd Beech House Beech Hill Office Campus Clonskeagh Dublin 4 Tel: (+353) (0)1 260 1255 Fax: (+353) (0)1 260 1263 Media Contact Contact Main Number
32
Novo Nordisk Limited 3-4 Upper Pembroke Street Dublin 2 Tel: (+353) (0)1 678 5989 Fax: (+353) (0)1 676 3259 Primary Media Contact Name: Owen Treacy Tel: (+353) (0)1 678 5989 Mob: (+353) (0)86 856 7224 Fax: (+353) (0)1 676 3259 Email: owtr@novonordisk.com Secondary Name: Yvette Murphy-Skov Tel: (+353) (0)1 678 5989 Mob: (+353) (0)86 850 0810 Fax: (+353) (0)1 676 3259 Email: YMS@novonordisk.com Nycomed Products Ltd 2051 Castle Drive Citywest Business Campus Dublin 24 Tel: (+353) (0)1 642 0021 Fax: (+353) (0)1 642 0020 Media Contact Contact Main Number Organon Laboratories Limited PO Box 2857 Drynam Road Tel: (+353) (0)1 463 7400 Fax: (+353) (0)1 459 6915 Media Contact Name: Brian Dawson Tel: (+44) 1 223 432 704 Mob: (+44) 7 887 630v975 Fax: (+44) 1 223 432 700 Email: brian.dawson@organon.co.uk
Section Two – IPHA Member Companies
McNeil Healthcare Johnson & Johnson Airton Road Tallaght Dublin 24 Tel: (+353) (0)1 466 5331 Media Contact Contact Main Number Pfizer Healthcare Ireland No.9 River Walk City West Business Campus Dublin 24 Tel: (+353) (0)1 467 6500 Fax: (+353) (0)1 467 6501 Media Contact Name: Tara Delaney Tel: (+353) (0)1 467 6566 Mob: (+353) (0)87 298 7958 Fax: (+353) (0)1 467 6501 Email:Tara.delaney@pfizer.com Pierre Fabre Ltd Hyde Abbey House 23 Hyde Street Winchester Hampshire 5023 7DR UK Tel: (+44) 1 962 874 400 Fax: (+44) 1 962 844 014 Media Contact Contact Main Number
Procter & Gamble (Health & Beauty Care) Ltd The Heights Brooklands Weybridge Surrey KT13 0XP UK Tel: (+44) 1 932 896 000 Fax: (+44) 1 932 896 200 Media Contact Contact Main Number Reckitt Benckiser Healthcare (Ireland) Ltd 7 Riverwalk Citywest Business Campus Dublin 24 Tel: (+353) (0)1 468 9200 Fax: (+353) (0)1 468 9299 Media Contact Name: Heather Ann McSharry Tel: (+353) (0)1 468 9200 Fax: (+353) (0)1 468 9299 Roche Products (Ireland) Ltd 3004 Lake Drive Citywest Naas Road Dublin 24 Tel: (+353) (0)1 469 0700 Fax: (+353) (0)1 469 0790 Media Contact Name: Sinéad O’ Rouke Tel: (+353) (0)1 469 0700 Mob: (+353) (0)86 044 1570 Fax: (+353) (0)1 469 0790 Email: Sinead.orourke@roche.com
33
The Stakeholder Handbook
Rottapharm Ltd Damastown Industrial Estate Mulhuddart Dublin 15 Tel: (+353) (0)1 885 2700 Fax: (+353) (0)1 885 2792 Media Contact Contact Main Number sanofi-aventis Ireland Ltd. 18 Riverwalk National Digital Park Citywest Business Campus Dublin 24 Tel: (+353) (0)1 403 5600 Fax: (+353) (0)1 403 5601 Media Contact Name: Sinead Duffy Tel: (+353) (0)1 403 5643 Mob: (+353) (0)86 600 8089 Fax: (+353) (0)1 403 5603 Email: sinead.duffy@sanofiaventis.com Sanofi Pasteur MSD Second Floor Unit A Cookstown Court Old Belgard Road Tallaght Dublin 24 Tel: (+353) (0)1 468 5600 Fax: (+353) (0)1 420 3588 Website: www.spmsd.co.uk Media Contact Contact Main Number
34
Schering Plough Pharmaceuticals (Ireland) Limited 6th Floor, Block 14 (North Block) Rockfield Central Dundrum Dublin 16 Tel: (+353) (0)1 215 6030 Fax: (+353) (0)1 215 6039 Primary Media Contact Name: Jim Baxter Tel: (+44) 1 707 363 990 Mob: (+44) 7 768 498 522 Fax: (+44) 1 707 363 958 Email: jim.baxter@spcorp.com Secondary Name: Claire Beuster Tel: (+44) 1 707 363 986 Fax: (+44) 1 707 363 958 Email:claire.beuster@spcorp.com Servier Laboratories (Ireland) Limited Block 2 West Pier Business Campus Old Dunleary Road Dun Laoghaire Co Dublin Tel: (+353) (0)1 663 8110 Fax: (+353) (0)1 663 8120 Media Contact Name: Dr Loic de Chassey Tel: (+353) (0)1 663 8110 Mob: (+353) (0)86 837 4952 Fax: (+353) (0)1 663 8120 Email: Loic.dechassey@ie.netgrs.com
Section Two – IPHA Member Companies
Shire Pharmaceuticals Ireland Ltd 5 Riverwalk Citywest Business Campus Dublin 24 Tel: (+353) (0)1 429 7700 Fax: (+353) (0)1 429 7701 Media Contact Name: Jessica Mann Tel: (+44) 1 256 894 000 Email: jmann@shire.com
Stiefel Laboratories Holtspur Lane Woodburn Green High Wycombe Bucks HP10 0AU UK Tel: (+44) 1 628 411 500 Fax: (+44) 1 628 810 021 Media Contact Contact Main Number
Solvay Healthcare Limited United Drug House Magna Drive Magna Business Park Citywest Road Dublin 24 Tel: (+353) (0)1 463 7387 Fax: (+353) (0)1 463 7388 Media Contact Name: Martial Tardy Tel: (+32) 2 509 7230 Mob: (+32) 475 830 114 Fax: (+32) 2 509 72 40 Email: Martial.tardy@solvay.com Secondary Name: Nicola Mellotte Tel: (+353) (0)1 463 7387 Fax: (+353) (0)1 463 7388 Email: Nicola.mellotte@solvay.com
Tillotts Pharma Ltd 25 Sandyford Office Park Dublin 18 Tel: (+41) 619 352 614 Fax: (+41) 619 352 658 Media Contact Name: Mai Hanlon Tel: (+353) (0)1 294 2015 Fax: (+353) (0)1 294 2019 Email: mhanlon@tillots.com
SSL Healthcare Ireland Ltd Monarch Industrial Estate Belgard Road Dublin 24 Tel: (+353) (0)1 460 1925 Fax: (+353) (0)1 460 3740 Media Contact Name: Miriam Abel Tel: (+353) (0)1 460 1925 Fax: (+353) (0)1 404 1666 Email: miriam.abel@sslhealthcare.ie
UCB Pharma Limited United Drug House Magna Drive CityWest Road Tallaght Dublin 24 Tel: (+353) (0)1 463 7395 Fax: (+353) (0)1 463 7396 Media Contact Name: Heather Williams Tel: (+32) 2 599 933 Email: Heather.Williams@ucbgroup.com
35
The Stakeholder Handbook
Wyeth Consumer Healthcare Plaza 254 Blanchardstown Corporate Park 2, Ballycoolin Blanchardstown Dublin 15 Tel: (+353) (0)1 449 3500 Fax: (+353) (0)1 449 3522 Media Contact Name: Geraldine O’ Connor Tel: (+353) (0)1 449 3500 Wyeth Pharmaceuticals Plaza 254 Blanchardstown Corporate Park 2, Ballycoolin Blanchardstown Dublin 15 Tel: (+353) (0)1 449 3500 Fax: (+353) (0)1 449 3522 Media Contact Name: Geraldine O’ Connor Tel: (+353) (0)1 449 3500
36
Section Two – IPHA Member Companies
MEMBER COMPANY BY THERAPEUTIC CATEGORY ALIMENTARY SYSTEM General Bayer Consumer Care Merck Serono Merck Sharp & Dohme Ireland (Human Health) Ltd Roche Products (Ireland) Ltd Shire Pharmaceuticals Ireland Ltd Limited SSL Healthcare Ireland Ltd Antispasmodics (Anticholinergics) Boehringer Ingelheim Ireland Limited Solvay Healthcare Limited
Pancreatic Enzymes Solvay Healthcare Limited Ulcer (Peptic Ulcers) Astellas Pharma Ltd AstraZeneca Pharmaceuticals (Ireland) Ltd GlaxoSmithKline (GSK) Janssen-Cilag Limited Wyeth Pharmaceuticals Other Biogen Idec (Ireland) Ltd GlaxoSmithKline (GSK) Janssen-Cilag Limited
CIRCULATORY SYSTEM Diarrhoea Janssen-Cilag Limited McNeil Healthcare
Angina Abbott Laboratories (I) Ltd Bayer Schering Pharma Bristol-Myers Squibb Inflammatory Bowel Disease Pharmaceuticals AstraZeneca Pharmaceuticals Cephalon Pharma (Ireland) (Ireland) Ltd Limited Biogen Idec (Ireland) Ltd Schering-Plough Pharmaceuticals Merck Serono Mundipharma Pharmaceuticals (Ireland) Limited Company Tillotts Pharma Ltd Novartis Ireland Ltd Servier Laboratories (Ireland) Laxatives Limited Boehringer Ingelheim Ireland UCB Pharma Limited Limited Mundipharma Pharmaceuticals Company Procter & Gamble (Health and Beauty Care) Ltd Reckitt Benckiser Healthcare (Ireland) Ltd Solvay Healthcare Limited
37
The Stakeholder Handbook
Hypertension A. Menarini Pharmaceuticals Ireland Ltd Abbott Laboratories (I) Ltd Astellas Pharma Ltd AstraZeneca Pharmaceuticals (Ireland) Ltd Bayer Schering Pharma Boehringer Ingelheim Ireland Limited Bristol-Myers Squibb Pharmaceuticals Merck Serono Merck Sharp & Dohme Ireland (Human Health) Ltd Mundipharma Pharmaceuticals Company Novartis Ireland Ltd Pfizer Healthcare Ireland Roche Products (Ireland) Ltd Servier Laboratories (Ireland) Limited Shire Pharmaceuticals Ireland Ltd Solvay Healthcare Limited Diuretics LEO Pharma Mundipharma Pharmaceuticals Company Novartis Ireland Ltd Roche Products (Ireland) Ltd Servier Laboratories (Ireland) Limited Anticoagulants (Blood Thinners) Boehringer Ingelheim Ireland Limited LEO Pharma Pfizer Healthcare Ireland Wyeth Pharmaceuticals
38
Arrhythmia (Abnormal Heart Rhythm) Abbott Laboratories (I) Ltd AstraZeneca Pharmaceuticals (Ireland) Ltd Boehringer Ingelheim Ireland Limited Bristol-Myers Squibb Pharmaceuticals Myocardial Infarction (Heart Attack) Alliance Pharmaceuticals Ireland Boehringer Ingelheim Ireland Limited Bristol-Myers Squibb Pharmaceuticals Merck Serono Novartis Ireland Ltd Roche Products (Ireland) Ltd Servier Laboratories (Ireland) Limited Solvay Healthcare Limited Congestive Heart Failure A. Menarini Pharmaceuticals Ireland Ltd AstraZeneca Pharmaceuticals (Ireland) Ltd Bristol-Myers Squibb Pharmaceuticals GlaxoSmithKline (GSK) Merck Serono Novartis Ireland Ltd Pfizer Healthcare Ireland Roche Products (Ireland) Ltd Servier Laboratories (Ireland) Limited Solvay Healthcare Limited
Section Two – IPHA Member Companies
High Cholesterol AstraZeneca Pharmaceuticals (Ireland) Ltd Bristol-Myers Squibb Pharmaceuticals Merck Serono Merck Sharp & Dohme Ireland (Human Health) Ltd Novartis Ireland Ltd Pfizer Healthcare Ireland Schering-Plough Pharmaceuticals (Ireland) Limited Solvay Healthcare Limited
Depression Astellas Pharma Ltd Boehringer Ingelheim Ireland Limited GlaxoSmithKline (GSK) Lundbeck (Ireland) Ltd Novartis Ireland Ltd Pfizer Healthcare Ireland Roche Products (Ireland) Ltd Schering-Plough Pharmaceuticals (Ireland) Limited Solvay Healthcare Limited Wyeth Pharmaceuticals
Stroke Allergan Pharmaceuticals Ireland Ltd Boehringer Ingelheim Ireland Limited Cephalon Pharma (Ireland) Limited Ipsen Pharmaceuticals Limited Servier Laboratories (Ireland) Limited UCB Pharma Limited
Schizophrenia AstraZeneca Pharmaceuticals (Ireland) Ltd Janssen-Cilag Limited Lundbeck (Ireland) Ltd Novartis Ireland Ltd Pfizer Healthcare Ireland
Other GlaxoSmithKline (GSK) Roche Products (Ireland) Ltd
CNS General A. Menarini Pharmaceuticals Ireland Ltd Bristol-Myers Squibb Pharmaceuticals GlaxoSmithKline (GSK) Ipsen Pharmaceuticals Limited Servier Laboratories (Ireland) Limited
Alzheimer’s Disease Lundbeck (Ireland) Ltd Novartis Ireland Ltd Pfizer Healthcare Ireland Shire Pharmaceuticals Ireland Ltd Epilepsy AstraZeneca Pharmaceuticals (Ireland) Ltd Cephalon Pharma (Ireland) Limited Eisai Limited GlaxoSmithKline (GSK) Janssen-Cilag Limited Novartis Ireland Ltd Pfizer Healthcare Ireland UCB Pharma Limited
39
The Stakeholder Handbook
Insomnia AstraZeneca Pharmaceuticals (Ireland) Ltd Bayer Schering Pharma Wyeth Pharmaceuticals
Attention Deficit/Hyperactivity Disorder (ADHD) Janssen-Cilag Limited Novartis Ireland Ltd UCB Pharma Limited
Multiple Sclerosis Bayer Schering Pharma Biogen Idec (Ireland) Ltd Merck Serono
-Other Allergan Pharmaceuticals Ireland Ltd GlaxoSmithKline (GSK) Lundbeck (Ireland) Ltd
Parkinson’s Disease Boehringer Ingelheim Ireland Limited GlaxoSmithKline (GSK) Lundbeck (Ireland) Ltd Roche Products (Ireland) Ltd Solvay Healthcare Limited UCB Pharma Limited
ANALGESIA
Analgesics (Pain relievers) Abbott Laboratories (I) Ltd A. Menarini Pharmaceuticals Ireland Ltd Astellas Pharma Ltd AstraZeneca Pharmaceuticals Sleep Disorders (Ireland) Ltd Bayer Schering Pharma Bayer Consumer Care UCB Pharma Limited Bristol-Myers Squibb Pharmaceuticals Nausea Cephalon Pharma (Ireland) GlaxoSmithKline (GSK) Limited McNeil Healthcare Eisai Limited Merck Serono GlaxoSmithKline (GSK) Merck Sharp & Dohme Ireland Grüenthal Pharma Ltd (Human Health) Ltd Janssen-Cilag Limited Reckitt Benckiser Healthcare Merck Sharp & Dohme Ireland (Ireland) Ltd (Human Health) Ltd Roche Products (Ireland) Ltd Shire Pharmaceuticals Ireland Ltd Mundipharma Pharmaceuticals Company SSL Healthcare Ireland Ltd Novartis Ireland Ltd Pfizer Healthcare Ireland Anxiety Disorders Reckitt Benckiser Healthcare Astellas Pharma Ltd (Ireland) Ltd AstraZeneca Pharmaceuticals Roche Products (Ireland) Ltd (Ireland) Ltd Shire Pharmaceuticals Ireland Ltd Lundbeck (Ireland) Ltd SSL Healthcare Ireland Ltd Roche Products (Ireland) Ltd UCB Pharma Limited Wyeth Pharmaceuticals Wyeth Consumer Healthcare
40
Section Two – IPHA Member Companies
Migraine A. Menarini Pharmaceuticals Ireland Ltd AstraZeneca Pharmaceuticals (Ireland) Ltd GlaxoSmithKline (GSK) Janssen-Cilag Limited Reckitt Benckiser Healthcare (Ireland) Ltd Roche Products (Ireland) Ltd
ANAESTHESIA Abbott Laboratories (I) Ltd AstraZeneca Pharmaceuticals (Ireland) Ltd Boehringer Ingelheim Ireland Limited GlaxoSmithKline (GSK) Janssen-Cilag Limited Schering-Plough Pharmaceuticals (Ireland) Limited
RHEUMATOLOGY (rheumatoid arthristis, gout, muscle spasm) Abbott Laboratories (I) Ltd Alliance Pharmaceuticals Ireland Astellas Pharma Ltd Boehringer Ingelheim Ireland Limited Bristol-Myers Squibb Pharmaceuticals Merck Sharp & Dohme Ireland (Human Health) Ltd Novartis Ireland Ltd Roche Products (Ireland) Ltd Rottapharm Limited Schering-Plough Pharmaceuticals (Ireland) Limited Shire Pharmaceuticals Ireland Ltd Wyeth Pharmaceuticals
HORMONES General Bristol-Myers Squibb Pharmaceuticals Diabetes Bayer Schering Pharma GlaxoSmithKline (GSK) Merck Serono Merck Sharp & Dohme Ireland (Human Health) Ltd Novartis Ireland Ltd Pfizer Healthcare Ireland Servier Laboratories (Ireland) Limited Solvay Healthcare Limited Erectile Dysfunction Bayer Schering Pharma Pfizer Healthcare Ireland Hormone Replacement AstraZeneca Pharmaceuticals (Ireland) Ltd Bayer Schering Pharma Janssen-Cilag Limited Novartis Ireland Ltd Solvay Healthcare Limited Wyeth Pharmaceuticals Human Growth Hormone Ipsen Pharmaceuticals Limited Merck Serono Pfizer Healthcare Ireland Other GlaxoSmithKline (GSK) Ipsen Pharmaceuticals Limited
41
The Stakeholder Handbook
UROLOGY (genital infections, urinary tract infections, renal and bladder disorders) Abbott Laboratories (I) Ltd Amgen Ireland Limited Astellas Pharma Ltd GlaxoSmithKline (GSK) Ipsen Pharmaceuticals Limited Janssen-Cilag Limited LEO Pharma Pfizer Healthcare Ireland Roche Products (Ireland) Ltd Shire Pharmaceuticals Ireland Ltd UCB Pharma Limited
ANTI-INFECTIVES General Procter & Gamble (Health and Beauty Care) Ltd Solvay Healthcare Limited Antibacterial (Antibiotics) Abbott Laboratories (I) Ltd Alliance Pharmaceuticals Ireland AstraZeneca Pharmaceuticals (Ireland) Ltd Bayer Schering Pharma GlaxoSmithKline (GSK) Gr端enthal Pharma Ltd Novartis Ireland Ltd Pfizer Healthcare Ireland Roche Products (Ireland) Ltd Antifungal (Fungal systemic) Bayer Consumer Care Cephalon Pharma (Ireland) Limited Janssen-Cilag Limited McNeil Healthcare
42
Novartis Ireland Ltd Pfizer Healthcare Ireland Reckitt Benckiser Healthcare (Ireland) Ltd Schering-Plough Pharmaceuticals (Ireland) Limited Servier Laboratories (Ireland) Limited UCB Pharma Limited Antiviral Abbott Laboratories (I) Ltd AstraZeneca Pharmaceuticals (Ireland) Ltd Bristol-Myers Squibb Pharmaceuticals GlaxoSmithKline (GSK) Pfizer Healthcare Ireland Roche Products (Ireland) Ltd Schering-Plough Pharmaceuticals (Ireland) Limited Wyeth Pharmaceuticals HIV Infection/Aids Abbott Laboratories (I) Ltd Boehringer Ingelheim Ireland Limited Bristol-Myers Squibb Pharmaceuticals GlaxoSmithKline (GSK) Janssen-Cilag Limited Merck Sharp & Dohme Ireland (Human Health) Ltd Pfizer Healthcare Ireland Roche Products (Ireland) Ltd
Section Two – IPHA Member Companies
IMMUNOLOGY
RESPIRATORY
Vaccines GlaxoSmithKline (GSK) Procter & Gamble (Health and Beauty Care) Ltd Sanofi Pasteur MSD Solvay Healthcare Limited Wyeth Pharmaceuticals
Asthma Astellas Pharma Ltd AstraZeneca Pharmaceuticals (Ireland) Ltd Boehringer Ingelheim Ireland Limited GlaxoSmithKline (GSK) Merck Sharp & Dohme Ireland (Human Health) Ltd Novartis Ireland Ltd
Immunosuppressants A. Menarini Pharmaceuticals Abbott Laboratories (I) Ltd Alliance Pharmaceuticals Ireland Astellas Pharma Ltd GlaxoSmithKline (GSK) Novartis Ireland Ltd Wyeth Pharmaceuticals
DIETETICS (vitamins and dietary supplements, antiobesity, anaemia) A. Menarini Pharmaceuticals Ireland Ltd Abbott Laboratories (I) Ltd Amgen Ireland Limited Allergan Pharmaceuticals Ireland Ltd Boehringer Ingelheim Ireland Limited Bristol-Myers Squibb Pharmaceuticals Janssen-Cilag Limited Novartis Consumer Health Novartis Ireland Limited Roche Products (Ireland) Ltd Shire Pharmaceuticals Ireland Ltd SSL Healthcare Ireland Ltd UCB Pharma Limited LEO Pharma
Chronic Obstructive Pulmonary Disease AstraZeneca Pharmaceuticals (Ireland) Ltd Bayer Schering Pharma Boehringer Ingelheim Ireland Limited GlaxoSmithKline (GSK) Mundipharma Pharmaceuticals Company Pfizer Healthcare Ireland Cystic Fibrosis Bayer Schering Pharma Novartis Ireland Ltd Roche Products (Ireland) Ltd Cough and Cold GlaxoSmithKline (GSK) Procter and Gamble (Health and Beauty Care) Ltd Reckitt Benckiser Healthcare (Ireland) Ltd Wyeth Consumer Healthcare
43
The Stakeholder Handbook
OTOLARYNGOLOGY (ear, nose and throat) Alliance Pharmaceuticals Ireland AstraZeneca Pharmaceuticals (Ireland) Ltd Boehringer Ingelheim Ireland Limited Bristol-Myers Squibb Pharmaceuticals GlaxoSmithKline (GSK) Janssen-Cilag Limited Meda Novartis Consumer Health Novartis Ireland Limited Pfizer Healthcare Ireland Reckitt Benckiser Roche Products (Ireland) Ltd Schering-Plough Pharmaceuticals (Ireland) Limited Servier Laboratories (Ireland) Limited SSL Healthcare Ireland Ltd UCB Pharma Limited
OPHTHALMOLOGY (eye) Allergan Pharmaceuticals Ireland Ltd Ipsen Pharmaceuticals Limited LEO Pharma Merck Sharp & Dohme Ireland (Human Health) Ltd Novartis Ireland Ltd Pfizer Healthcare Ireland Reckitt Benckiser Healthcare (Ireland) Ltd Roche Products (Ireland) Ltd UCB Pharma Limited
44
ALLERGY A. Menarini Pharmaceuticals Ireland Ltd AstraZeneca Pharmaceuticals (Ireland) Ltd GlaxoSmithKline (GSK) Schering-Plough Pharmaceuticals (Ireland) Limited UCB Pharma Limited
DERMATOLOGY (psoriasis, eczema, acne, scabies) Abbott Laboratories (I) Ltd Allergan Pharmaceuticals Ireland Ltd Alliance Pharmaceuticals Ireland Astellas Pharma Ltd Bayer Consumer Care Bayer Schering Pharma Cephalon Pharma (Ireland) Limited GlaxoSmithKline (GSK) Janssen-Cilag Limited LEO Pharma Merck Serono Novartis Ireland Ltd Pierre Fabre Ltd Reckitt Benckiser Healthcare (Ireland) Ltd Roche Products (Ireland) Ltd Schering-Plough Pharmaceuticals (Ireland) Limited Shire Pharmaceuticals Ireland Ltd SSL Healthcare Ireland Ltd Stiefel Laboratories UCB Pharma Limited Wyeth Pharmaceuticals
Section Two – IPHA Member Companies
CONTRACEPTION Bayer Schering Pharma Janssen-Cilag Limited Schering-Plough Pharmaceuticals (Ireland) Limited SSL Healthcare Ireland Ltd Wyeth Pharmaceuticals
OBSTETRICS & GYNAECOLOGY Breast Disorders AstraZeneca Pharmaceuticals (Ireland) Ltd Bristol-Myers Squibb Pharmaceuticals Meda Novartis Ireland Ltd Pfizer Healthcare Ireland Roche Products (Ireland) Ltd Hormone Replacement AstraZeneca Pharmaceuticals (Ireland) Ltd Bayer Schering Pharma Janssen-Cilag Limited Novartis Ireland Ltd Solvay Healthcare Limited Wyeth Pharmaceuticals Osteoporosis A. Menarini Pharmaceuticals Ireland Ltd Amgen Ireland Limited GlaxoSmithKline (GSK) Merck Sharp & Dohme Ireland (Human Health) Ltd Pfizer Healthcare Ireland Roche Products (Ireland) Ltd Servier Laboratories (Ireland) Limited
Shire Pharmaceuticals Ireland Ltd Wyeth Consumer Healthcare Wyeth Pharmaceuticals Obstetrics AstraZeneca Pharmaceuticals (Ireland) Ltd Novartis Ireland Ltd Pfizer Healthcare Ireland Reproductive Health Ipsen Pharmaceuticals Limited Meda Merck Serono Pfizer Healthcare Ireland Schering-Plough Pharmaceuticals (Ireland) Limited Other Bayer Schering Pharma Ipsen Pharmaceuticals Limited
ONCOLOGY (cancer) Amgen Ireland Limited Astellas Pharma Ltd AstraZeneca Pharmaceuticals (Ireland) Ltd Bayer Schering Pharma Biogen Idec (Ireland) Ltd Bristol-Myers Squibb Pharmaceuticals Celgene Limited Cephalon Pharma (Ireland) Limited GlaxoSmithKline (GSK) Ipsen Pharmaceuticals Limited Janssen-Cilag Limited Merck Serono Novartis Ireland Ltd Pfizer Healthcare Ireland
45
The Stakeholder Handbook
Pierre Fabre Ltd Procter & Gamble (Health and Beauty Care) Ltd Roche Products (Ireland) Ltd Sanofi Pasteur MSD Schering-Plough Pharmaceuticals (Ireland) Limited Wyeth Pharmaceuticals
NICOTINE REPLACEMENT GlaxoSmithKline (GSK) McNeil Healthcare Novartis Consumer Health Pfizer Healthcare Ireland
TOXICOLOGY Alliance Pharmaceuticals Ireland Bristol-Myers Squibb Pharmaceuticals GlaxoSmithKline (GSK) LEO Pharma Merck Serono Novartis Ireland Ltd Roche Products (Ireland) Ltd UCB Pharma Ltd
DIAGNOSTIC AGENTS (imaging) Bayer Schering Pharma
46